




The relative strengths and weaknesses of Rigel Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rigel Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 201% points. The greatest weakness of Rigel Pharmaceuticals INC is the variable Other Revenues, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 392%, being 158% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	250,233
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,527
Liabilities, Non-Current	0
Other Assets	1,991
Other Compr. Net Income	0
Other Expenses	25
Other Liabilities	0
Other Net Income	5,170
Other Revenues	0
Property and Equipment	4,882
Research and Development	69,350
Selling, General and Administrative Expense	21,768

Output Variable	Value in 1000 USD
Assets	257,106
Liabilities	11,527
Expenses	91,143
Revenues	0
Stockholders Equity	245,579
Net Income	-85,973
Comprehensive Net Income	-85,973
BaseVar	182,473
ECR before LimitedLiability	335%
Economic Capital Ratio	392%